Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: April 2015

Will Prescription Drug Prices Be a Big Issue for 2016 Contenders?

Washington, DC, April 23, 2015 ― The National Journal’s Dylan Scott reports that headlines consistently warn that prices for prescription drugs are spiking higher and higher. Half of Americans are taking them regularly.  Obamacare touched most corners of the health care industry, but didn’t address drug costs specifically.

Now Hillary Clinton is signaling that prescription-drug affordability will be a priority in her campaign.  According to MSNBC, while campaigning last week in Iowa, Mrs. Clinton said, “We need to drive a harder bargain negotiating with drug companies about the costs of drugs.”  She noted the “height of ironies” that medications developed in the United States often are sold more cheaply overseas.

According to Scott, the issue of prescription drug prices, both brand and generic, is shaping up to be one of the next frontiers for health care reform in this country.  Continue reading

BioNJ and HINJ Commentary: To Save Patients, Keep New Jersey’s Life Sciences Industry Healthy

Cherry Hill, NJ, April 22, 2015 The Courier-Post on April 16 published an op-ed authored by Debbie Hart, President and CEO of BioNJ, and Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ).

*    *    *

New Jersey is an AIDS “hotspot,” according to CBS News.  The statistics show why. In 2012, nearly 2,000 state residents were diagnosed with HIV/AIDS.  Roughly 400 people died from the disease.

Thanks to advances in treatment, however, this disease is no longer a death sentence. Fatality rates from AIDS have dropped nearly 85 percent over the last two decades, and are still declining. Continue reading

NJ Department of Health Recognizes Medical Laboratory Professionals Week

Trenton, NJ, April 22, 2015 ― New Jersey Health Commissioner Mary E. O’Dowd recognized Medical Laboratory Professionals Week, April 19-25, by commending New Jersey’s laboratory professionals are an essential part of every aspect of healthcare, including medical diagnosis and public health prevention.

“New Jersey’s laboratory professionals play a vital role in health care and especially in protecting the public health, as we saw during the Ebola outbreak this past year,” said Commissioner O’Dowd.   Continue reading

Study Debunks Link Between Autism and Childhood Vaccines

Newark, NJ, April 22, 2015 ― Kathleen O’Brien today reports in The Star-Ledger that a large study released Tuesday in JAMA, the Journal of the American Medical Association, finds no link between autism and childhood vaccines, even for those with an older sibling who has autism.

The study, which was led by Anjali Jain of the Lewin Group, determined the vaccination history and autism diagnoses of more than 95,000 children by accessing the insurance claims database of a large commercial health plan. Continue reading

PhRMA Member Companies Invested $51.2 Billion in R&D in 2014; Over $600 Billion Since 2000

Washington, DC, April 21, 2015 ― Pharmaceutical Research and Manufacturers of America’s (PhRMA) member companies invested an estimated $51.2 billion last year in the research and development (R&D) of new innovative treatments and cures.  The figure represents the majority of all biopharmaceutical R&D spending — both public and private — in the United States.

The new R&D numbers, the result of a recent survey of PhRMA member companies, are highlighted in the newly released PhRMA 2015 Biopharmaceutical Research Industry Profile as well as a new industry chart pack, Biopharmaceuticals in Perspective.

Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures. Continue reading

Researchers Say Fake, Low-Quality Drugs Are a ‘Global Pandemic’

Washington, DC, April 21, 2015 ― Brady Dennis today reports in The Washington Post that fake and substandard drugs are responsible for tens of thousands of deaths around the globe each year, and the persistent lack of reliable medicines in poor countries threatens to roll back decades of efforts to combat malaria, tuberculosis, HIV/AIDS and other conditions, researchers said Monday.

“The pandemic of falsified and substandard medicines is pervasive and underestimated, particularly in low- and middle-income countries where drug and regulatory systems are weak or non-existent,” Jim Herrington, a University of North Carolina public health professor who co-edited a collection of articles on the topic published in the American Journal of Tropical Medicine and Hygiene, said in a statement. Continue reading

National Infant Immunization Week Highlights Importance of Childhood Disease Protection

Trenton, NJ, April 21, 2015 ― Raising awareness about the importance of childhood immunizations in protecting children, families and communities, New Jersey Department of Health State Epidemiologist Dr. Tina Tan will visit the Center for Health Education, Medicine, & Dentistry (CHEMED) during National Infant Immunization Week (NIIW), an annual observance held since 1994.

CHEMED, a federally qualified health center, will focus on boosting immunization rates in their clinic for those children birth through age two years with a goal of vaccinating approximately 600 children by the end of NIIW.

This event will be held on April 22 at 11:30 am at CHEMED, 1771 Madison Avenue, Lakewood. Continue reading

New Jersey Seeks a Way to Recover Its Innovation Sector

Woodland Park, NJ, April 20, 2015 ― What can New Jersey — once the home of storied inventors like Thomas Edison and the Bell and Sarnoff labs — do to get its innovation mojo back?

In a story published in yesterday’s Record, Hugh Morley reported that that question held center stage at a forum of business and civic leaders in Newark last week that outlined a way to jump-start New Jersey’s struggling economy by tapping into the traits that once made the state a thriving, innovation powerhouse.

Consultants from the Brookings Institution, the Washington, D.C., think tank, told the forum that the state’s best approach would be to nurture “advanced industries” — R&D-intensive sectors driven by workers skilled in science, technology, engineering and mathematics, known as STEM. Continue reading

PhRMA Applauds 2015 We Work For Health Champion Award Winners

Washington, DC, April 20, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) on April 17 honored 13 employees from 12 biopharmaceutical companies as “We Work For Health Champions” for their extraordinary efforts in policy advocacy and community service.

Established in 2009, the We Work for Health Champion Awards were created by the biopharmaceutical industry to honor employees who have not only excelled in their careers, but have also shown an outstanding commitment to their communities through advocacy, community outreach, educational programs, community service and corporate education programs. Continue reading

BIO Honors Rep. Leonard Lance as a Legislator of the Year 2015

Washington, DC, April 19, 2015 ― The Biotechnology Industry Organization (BIO) honored U.S. Representative Leonard Lance (R-NJ-7) as a Legislator of the Year for 2015. Representative Lance received the award in conjunction with BIO’s Legislative Day Fly-In, which was held here last week.

“I am honored by this recognition.  The 21st century will see cures for some of the world’s most pressing health challenges as long as the biotechnology and life science sector are empowered to innovate,” said Congressman Lance after the presentation.  Continue reading